Antibody response to pneumococcal capsular polysaccharide vaccine in Down syndrome patients

B.T. Costa-Carvalho¹, R.M.A. Martinez¹, A.T.N. Dias², C.A. Kubo³, P. Barros-Nunes³, L. Leiva⁴, D. Solé³, M.M.S. Carneiro-Sampaio¹,², C.K. Naspitz¹ and R.U. Sorensen¹,⁵

Abstract

The majority of children with Down syndrome (DS) tend to have frequent bacterial infections including recurrent respiratory infections. Our objective was to evaluate the production of antibodies to pneumococcal polysaccharide antigens after active immunization in DS subjects. IgG antibodies to pneumococcal serotypes (1, 3, 6B, 9V, and 14) were measured before and 6 weeks after immunization with a 23-valent pneumococcal vaccine (Pneumo23®, Pasteur-Merieux) in 6- to 13-year-old DS children (N = 17) and in aged-matched normal controls (N = 30). An adequate response was defined as a 4-fold increase over baseline or a post-immunization level of specific pneumococcal serotype antibody ≥ 1.3 µg/mL. After immunization, all DS children had an increase in post-immunization levels against all serotypes analyzed. A 4-fold or more increase was observed in all DS children concerning serotypes 1 and 14, in 90% of subjects for serotypes 3 and 9V, and in 65% for serotype 6B. Regarding this increase, 8 of the 17 DS children had an adequate response to all serotypes analyzed, 8/17 patients to 4 serotypes and 1/17 to 3 serotypes. However, when we compared post-immunization levels between DS children and controls, we observed lower levels in the former group (P < 0.05) for all serotypes except serotype 3. We conclude that pneumococcal polysaccharide immunization could be beneficial for these DS children.

Introduction

Down syndrome (DS) is the most common trisomy in liveborn children and the major known genetic cause of mental retardation (1). The incidence of DS in Latin American countries is approximately 1/700 live births (2). Despite advancements in treatment, pneumonia and other respiratory diseases are still the major causes of morbidity.
and mortality in DS children (3). Different aspects of the immune system have been studied in DS to obtain a better understanding of the increased risk of infection observed in affected individuals (4). Abnormalities in humoral and cell-mediated immunities and in phagocytic function have been reported (3-7).

Data concerning post-immunization antibody production in DS patients are variable. Antibody production to tetanus toxoid and influenza virus is decreased or normal (8,9), and isohemagglutinin titers and natural antibodies to Escherichia coli are normal (10). The antibody response to bacteriophage φX174 is impaired both in primary and secondary immunological responses (11). These facts argue for an impaired humoral response in DS patients. Polysaccharides are considered to be T-independent antigens and immunization with polysaccharide vaccines has been recommended as a diagnostic tool to evaluate patient ability to respond to those antigens (12). Nurmi et al. (13) observed a lower response to polysaccharide antigens in adult DS patients compared to controls. In the present study, we evaluated pneumococcal serotype antibodies before and after immunization with a 23-valent pneumococcal polysaccharide vaccine (Pneumo23®) in DS children.

Subjects and Methods

Seventeen non-institutionalized 6- to 13-year-old DS subjects attending a daily facility for mentally handicapped children (APAE- Associação dos Pais e Amigos dos Excepcionais, São Paulo) were studied (10 girls and 7 boys). None of them had a history of recurrent infections or cardiovascular malformations. Thirty age-matched healthy children living in the same area of São Paulo served as controls. All children were submitted to clinical examination and peripheral blood samples were obtained from each patient to quantify the levels of immunoglobulin (Ig; G, A, M), of IgG subclasses and of antibodies against polysaccharide pneumococcal serotypes 1, 3, 6B, 9V, and 14.

Anti-pneumococcal IgG antibodies against pneumococcal serotypes 1, 3, 6B, 9V, and 14 were determined using a modified ELISA protocol (14,15). Standard, control and DS children’s serum samples were pre-absorbed for 30 min at 37°C with Streptococcus pneumoniae C-polysaccharide (500 µg/mL in undiluted serum; Statens Serum Institut, Copenhagen, Denmark). The serotype-specific IgG antibody concentration (µg/mL) was calculated using a standard curve obtained for a serum pool that had been previously calibrated using the FDA 89-SF reference sample (CBER, U.S. Food and Drug Administration, Rockville, MD, USA).

Serum samples were collected before and 6 weeks after immunization with the 23-valent pneumococcal capsular polysaccharide vaccine (Pneumo23® Pasteur-Merieux, Marcy Etoile, Lyon, France). An adequate response to individual polysaccharide was arbitrarily defined as a post-immunization antibody concentration equal to or higher than 1.3 µg/mL or a minimum 4-fold increase over the baseline value (14,15).

The Wilcoxon test was applied to compare pre- and post-IgG anti-pneumococcal serotype levels in DS patients, and the Mann-Whitney test was used to compare these antibodies between DS children and controls. The study was approved by APAE and by the UNIFESP-EPM Ethics Committee. The parents of the children participating in the study gave a written informed consent.

Results

Normal serum IgA and IgM levels were observed in DS children. Compared to normal values, all DS children but one had a serum IgG level above the 97th percentile, and 8/17 of them had IgG levels higher than 2,000 mg/dL. DS children showed a tendency to higher levels of serum IgG1 and IgG3 compared to controls. In 13 of 17 and in 12 of 17 DS
children, IgG1 and IgG3 levels were higher than the 97th percentile, respectively. In contrast, serum IgG2 levels below the 50th percentile were observed in 15/17 (88%) subjects. Two DS children had serum IgG2 levels below the 3rd percentile associated with IgG4 deficiency and they did not have any recurrent infections. Almost 53% of DS children had undetectable serum IgG4 levels.

Compared to controls, pre-immunization antibody levels to pneumococcus were significantly lower in DS children for all serotypes evaluated and both groups showed a significant increase of post-immunization compared with pre-immunization levels (Table 1). A 4-fold or more increase was observed in all subjects for serotypes 1 and 14, in 90% of subjects for serotypes 3 and 9V, and in 65% for serotype 6B. Controls had an adequate production of antibodies to all serotypes. The mean increase (post/pre-ratio) of IgG anti-pneumococcal serotype antibodies was higher than 7 for DS children, except for serotype 3 (Table 1, Figure 1). On

Table 1. Mean pre- and post-immunization (Pneumo23®) antibody levels and post/pre-ratio in children with Down syndrome (N = 17) and age-matched controls (N = 30).

<table>
<thead>
<tr>
<th>Serotype</th>
<th>Down syndrome</th>
<th>Controls</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Pre-</td>
<td>Post-</td>
</tr>
<tr>
<td>1 GM</td>
<td>0.20</td>
<td>1.54**</td>
</tr>
<tr>
<td>95% CI</td>
<td>0.13-0.54</td>
<td>1.35-2.87</td>
</tr>
<tr>
<td>3 GM</td>
<td>0.66</td>
<td>1.94**</td>
</tr>
<tr>
<td>95% CI</td>
<td>0.42-1.99</td>
<td>1.65-2.86</td>
</tr>
<tr>
<td>6B GM</td>
<td>0.25</td>
<td>1.29*</td>
</tr>
<tr>
<td>95% CI</td>
<td>0.17-0.57</td>
<td>0.82-3.78</td>
</tr>
<tr>
<td>9V GM</td>
<td>0.17</td>
<td>1.28*</td>
</tr>
<tr>
<td>95% CI</td>
<td>0.12-0.4</td>
<td>0.84-2.95</td>
</tr>
<tr>
<td>14 GM</td>
<td>0.78</td>
<td>3.53*</td>
</tr>
<tr>
<td>95% CI</td>
<td>0.65-1.87</td>
<td>1.93-12.8</td>
</tr>
</tbody>
</table>

Data are reported as means and range. GM = geometric mean; 95% CI = 95% confidence interval.

*P < 0.001 = post > pre. **P < 0.001 = Down syndrome > controls post/pre-ratio Down syndrome vs control. +P < 0.05 = post-control > post-Down syndrome (Wilcoxon and Mann-Whitney tests).
the basis of the increase, eight of the 17 DS children had an adequate response to all serotypes analyzed, 8/17 patients to 4 serotypes and 1/17 to 3 serotypes. However, when we compared post-immunization levels between DS children and controls, we observed lower levels in the former group (P < 0.05) to all serotypes except serotype 3 (Table 1). No DS child had levels of anti-pneumococcal IgG equal to or higher than 1.3 µg/mL for serotypes 1 and 9 pre- or post-immunization. Three DS children presented levels equal to or higher than 1.3 µg/mL for serotype 3, 1/17 DS children for serotype 6B, and 6/17 DS children for serotype 14.

DS children showed a significantly elevated post/pre ratio compared to controls (Table 1). Two DS children with IgG2 deficiency had an appropriate response to the 23-valent pneumococcal polysaccharide vaccine.

Discussion

It is well recognized that DS children have increased susceptibility to infections, mainly respiratory ones. They also have an increased risk of leukemias and other malignancies, as well as a higher incidence of auto-antibodies. A number of immunologic abnormalities have been noted in DS children although most of them have no clear immune dysfunction (3-5). Pneumococcal vaccines have been recommended to groups of patients who are at high risk, or who experience severe or frequent diseases (16).

Increased serum IgG levels and decreased IgM levels have been reported in DS children in late childhood and adolescence (6), as well as an increase of these immunoglobulins in saliva (17). Our DS children had increased serum IgG levels compared to controls, reflecting an overstimulation of B lymphocytes mainly due to IgG1 and IgG3 isotypes since these levels were elevated in the majority of DS children. High serum levels of IgG1 and IgG3 have been reported in DS adults (18). Despite their high IgG levels, DS children have been recently shown to present a lower number of B lymphocytes compared to controls throughout childhood (19).

In adults, anti-polysaccharide antibodies are found mainly with IgM and IgG2 isotypes (20). A normal IgM level and a tendency to lower levels of IgG2 were observed in our DS children, in agreement with other reports (18). Two DS children, aged 8 and 10 years, had serum IgG2 levels below the 3rd percentile but showed an adequate increase of pneumococcal antibodies after immunization. Subnormal serum IgG2 levels do not necessarily reflect a functional immunodeficiency (21,22). An adequate response to pneumococcal antigens depends on an interaction between innate and adaptive immune responses. An inefficient release of mature T cells from the DS thymus to the spleen leads to decreased education of B cells by T cells which could explain the diminished antibody responses of DS B cells to bacterial and viral antigens (4). However, polysaccharide antigens are considered to be thymus-independent and repeated epitopes expressed by polysaccharides induce multivalent membrane immunoglobulin cross-linking on the B-cell surface resulting in activation and proliferation of theses cells (23).

A normal IgG antibody response to pneumococcal immunization has not been well defined but a 2- to 4-fold rise in antibody levels post-immunization generally reflects an adequate response. Several other variables should also be considered, i.e., the protective level may depend on the age of the individual and may differ for different pneumococcal serotypes (24-26). There is a delay in the ontogeny of the acquisition of the polysaccharide antigen response, which involves very poor immunogens for infants (27,28). A specific antibody response to polysaccharide antigens is complete in children over 2 years of age (24,29). Our DS
children were older than 5 years and had a significant increase in the levels of antibodies to all serotypes evaluated after immunization, although these levels were lower than those observed in controls. In spite of lower levels compared to normal controls, DS children showed a 7-fold mean increase in antibodies which suggests that they produced pneumococcal antibodies after immunization and that probably this vaccine could offer some protection for them.

In Brazil, the most prevalent pneumococcal serotypes isolated from invasive infections are 1, 5, 6, and 14 (30,31) and the serotype distribution for invasive pneumococcal diseases is age-related (32). Pre-immunization levels of serotype 14 antibody were higher than 1.3 µg/mL in 6/17 of our DS children, suggesting previous contact. However, the other serotypes were observed in only a few patients and their mean levels were significantly lower than those of normal controls. It was presumed that the DS children and normal controls were exposed to the same pneumococcal serotypes because they lived in the same city and were of similar socioeconomic status. Similar results were observed by others in DS adults and controls living in the same area (13).

The CDC’s Advisory Committee on Immunization Practices (ACIP) had previously recommended 23-valent pneumococcal polysaccharide vaccines for use among children over 2 years of age who had a high risk of pneumococcal disease, including those with chronic underlying diseases or who were immunocompromised. Today the ACIP recommends the new 7-valent pneumococcal conjugate vaccine (33). Although the conjugate vaccine has many advantages, it is very expensive and includes only 7 serotypes. Serotypes 1 and 5, which are not present in this vaccine, remain among the principal serotypes in Brazil, mainly in children with pneumonia (32). The polysaccharide vaccine may be an alternative for these patients over 2 years old in developing countries.

We conclude that DS children present an adequate increase of antibody levels after the pneumococcal polysaccharide vaccine and that they could derive some benefit from this vaccine.

Acknowledgments

We wish to thank APAE (Associação dos Pais e Amigos dos Excepcionais, São Paulo, SP, Brazil) and all the families who have collaborated with this study.

References

11. Lopez V, Ochs HD, Thuline HC, Davis SD, Wedgwood RJ. Defective antibody response to bacteriophage phici 174 in Down syn-


